Identification

Name
Medrogestone
Accession Number
DB09124
Type
Small Molecule
Groups
Approved
Description

Medrogestone (INN), also known as 6,17α-dimethyl-6-dehydroprogesterone, is a progestational agent derived from 17-methylprogesterone. It was conceived as an alternative for an orally effective option.[1] It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing.[7] It was never approved by the FDA.

Structure
Thumb
Synonyms
Not Available
External IDs
AY 62022 / AY-13615 / AY-13615S / AY-62022 / NSC-123018
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Colprone Tab 5mgTablet5 mgOralWyeth Ayerst Canada Inc.1996-10-252001-08-30Canada
Colprone Tab 5mgTablet5 mgOralAyerst Laboratories1969-12-311997-08-15Canada
Categories
UNII
077DN93G5B
CAS number
977-79-7
Weight
Average: 340.507
Monoisotopic: 340.24023027
Chemical Formula
C23H32O2
InChI Key
HCFSGRMEEXUOSS-JXEXPEPMSA-N
InChI
InChI=1S/C23H32O2/c1-14-12-17-18(21(3)9-6-16(25)13-20(14)21)7-11-23(5)19(17)8-10-22(23,4)15(2)24/h12-13,17-19H,6-11H2,1-5H3/t17-,18+,19+,21-,22-,23+/m1/s1
IUPAC Name
(1S,2R,10R,11S,14S,15S)-14-acetyl-2,8,14,15-tetramethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-6,8-dien-5-one
SMILES
[H][[email protected]@]12CC[[email protected]](C)(C(C)=O)[[email protected]@]1(C)CC[[email protected]@]1([H])[[email protected]@]2([H])C=C(C)C2=CC(=O)CC[[email protected]]12C

Pharmacology

Indication

Medrogestone is indicated as adjunct to treat endometial shedding in menopausal women, to treat secondary amenorrhea, to induce menses and to treat dysfunctional uterine bleeding in adult and adolescent women.[2]

Structured Indications
Not Available
Pharmacodynamics

Medrogestone was created as a more potent and orally active option of progesterone. In pre-clinical trials, medrogestone was proven to have four times more progestational activity than progesterone with a similar duration effect than the one found for 17-hydroxyprogesterone. Medrogestone was also able to maintain pregnancy and prevented ovulation in ovariectomized rats. Administration of medrogestone, alone or with premarin, prevented pregnancy, as well as it suppressed ovarian weight increase by nearly 100% of the tested individuals. Medrogestone does not produce any androgenic effect but it presented a marked anti-androgenic effect. It did not present an oestrogenic effect, nor changes in organ weight or histological appearance in adrenal glands or thymus and it does not present any anti-inflammatory effects.[1]

Mechanism of action

Medrogestone is a progestogen, thus its action is done under the same profile. These type of molecules are steroid hormones that bind and activate the progesterone receptor.[3] Its action may involve the suppression of gonadotropic hormones from the anterior portion of the pituitary gland and secondary suppression of testosterone. Medrogestone presents structural similarities to testosterone which allows it to compete for the androgen-receptor-protein receptor sites in prostatic cells.[4] Administration of medrogestone diminishes the response to endogenous hormones in tumor cells due to a reduction in hormone steroid receptors; this effect will translate into cytotoxic or antiproliferative effects.[2]

TargetActionsOrganism
AProgesterone receptor
ligand
Human
Absorption

When administered, medrogestone presents a very rapid gastrointestinal absorption with a bioavailability of 100%. The maximum serum concentration of medrogestone is 10-15 ng/ml.[5]

Volume of distribution
Not Available
Protein binding

Medrogestone, as presented for all progestogens, is highly bound to plasma proteins. It is mainly bound to albumin but it also binds to other plasma proteins like sex hormone binding globulin or corticosteroid-binding globulin.[5] The pharmacokinetics of medrogestone will depend on the degree of plasma protein bindind which makes this characteristic the main regulator of the tissue availability of medrogestone.[6]

Metabolism

The non-protein bound fraction of medrogestoneis available for metabolism.[6] The main route in the metabolism of medrogestone is hydroxylation.[5]

Route of elimination

The elimination time of medrogestone is of 36 hours.[5]

Half life

The half-life of medrogestone is reported to be of 4 hours.[5]

Clearance
Not Available
Toxicity

There were reports of increased urinary flow rates and total micturition volumes as well as sexual dysfunction and hyperglycemia.[4]

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,4-thiazolidinedioneThe serum concentration of 2,4-thiazolidinedione can be decreased when it is combined with Medrogestone.Investigational
AbciximabThe therapeutic efficacy of Abciximab can be decreased when used in combination with Medrogestone.Approved
AcarboseThe serum concentration of Acarbose can be decreased when it is combined with Medrogestone.Approved, Investigational
AcenocoumarolThe therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Medrogestone.Approved, Investigational
AcetohexamideThe serum concentration of Acetohexamide can be decreased when it is combined with Medrogestone.Approved, Investigational, Withdrawn
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Medrogestone.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Medrogestone.Experimental
AICA ribonucleotideThe serum concentration of AICA ribonucleotide can be decreased when it is combined with Medrogestone.Experimental, Investigational
AllicinThe serum concentration of Allicin can be decreased when it is combined with Medrogestone.Investigational
AlogliptinThe serum concentration of Alogliptin can be decreased when it is combined with Medrogestone.Approved
AmobarbitalThe serum concentration of Medrogestone can be decreased when it is combined with Amobarbital.Approved, Illicit
AmoxicillinThe serum concentration of Medrogestone can be decreased when it is combined with Amoxicillin.Approved, Vet Approved
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Medrogestone.Approved, Investigational, Withdrawn
AncrodThe therapeutic efficacy of Ancrod can be decreased when used in combination with Medrogestone.Approved, Investigational
Antithrombin III humanThe therapeutic efficacy of Antithrombin III human can be decreased when used in combination with Medrogestone.Approved
ApixabanThe therapeutic efficacy of Apixaban can be decreased when used in combination with Medrogestone.Approved
ArdeparinThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Medrogestone.Approved, Investigational, Withdrawn
ArgatrobanThe therapeutic efficacy of Argatroban can be decreased when used in combination with Medrogestone.Approved, Investigational
AspoxicillinThe serum concentration of Medrogestone can be decreased when it is combined with Aspoxicillin.Experimental
AzlocillinThe serum concentration of Medrogestone can be decreased when it is combined with Azlocillin.Approved
BalaglitazoneThe serum concentration of Balaglitazone can be decreased when it is combined with Medrogestone.Investigational
BarbexacloneThe serum concentration of Medrogestone can be decreased when it is combined with Barbexaclone.Experimental
BarbitalThe serum concentration of Medrogestone can be decreased when it is combined with Barbital.Illicit
BecaplerminThe therapeutic efficacy of Becaplermin can be decreased when used in combination with Medrogestone.Approved, Investigational
Bempedoic acidThe serum concentration of Bempedoic acid can be decreased when it is combined with Medrogestone.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Medrogestone.Approved, Investigational
BivalirudinThe therapeutic efficacy of Bivalirudin can be decreased when used in combination with Medrogestone.Approved, Investigational
BuforminThe serum concentration of Buformin can be decreased when it is combined with Medrogestone.Investigational, Withdrawn
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Medrogestone.Approved
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Medrogestone.Approved
CarbutamideThe serum concentration of Carbutamide can be decreased when it is combined with Medrogestone.Experimental
CastanospermineThe serum concentration of Castanospermine can be decreased when it is combined with Medrogestone.Experimental
CertoparinThe therapeutic efficacy of Certoparin can be decreased when used in combination with Medrogestone.Approved, Investigational
ChlorpropamideThe serum concentration of Chlorpropamide can be decreased when it is combined with Medrogestone.Approved, Investigational
ChlortetracyclineThe serum concentration of Medrogestone can be decreased when it is combined with Chlortetracycline.Approved, Investigational, Vet Approved
CiglitazoneThe serum concentration of Ciglitazone can be decreased when it is combined with Medrogestone.Experimental
Citric AcidThe therapeutic efficacy of Citric Acid can be decreased when used in combination with Medrogestone.Approved, Nutraceutical, Vet Approved
ClomocyclineThe serum concentration of Medrogestone can be decreased when it is combined with Clomocycline.Approved
Conestat alfaMedrogestone may increase the thrombogenic activities of Conestat alfa.Approved, Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Medrogestone.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Medrogestone.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Medrogestone.Experimental
Dabigatran etexilateThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Medrogestone.Approved
DalteparinThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Medrogestone.Approved
DanaparoidThe therapeutic efficacy of Danaparoid can be decreased when used in combination with Medrogestone.Approved, Withdrawn
DarexabanThe therapeutic efficacy of Darexaban can be decreased when used in combination with Medrogestone.Investigational
DemeclocyclineThe serum concentration of Medrogestone can be decreased when it is combined with Demeclocycline.Approved
DeoxyspergualinThe serum concentration of Deoxyspergualin can be decreased when it is combined with Medrogestone.Investigational
DesirudinThe therapeutic efficacy of Desirudin can be decreased when used in combination with Medrogestone.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Medrogestone.Approved
DextranThe therapeutic efficacy of Dextran can be decreased when used in combination with Medrogestone.Approved, Investigational, Vet Approved
Dextran 40The therapeutic efficacy of Dextran 40 can be decreased when used in combination with Medrogestone.Approved
Dextran 70The therapeutic efficacy of Dextran 70 can be decreased when used in combination with Medrogestone.Approved
Dextran 75The therapeutic efficacy of Dextran 75 can be decreased when used in combination with Medrogestone.Approved
DicoumarolThe therapeutic efficacy of Dicoumarol can be decreased when used in combination with Medrogestone.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Medrogestone.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Medrogestone.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Medrogestone.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Medrogestone.Approved, Investigational
DoxycyclineThe serum concentration of Medrogestone can be decreased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DulaglutideThe serum concentration of Dulaglutide can be decreased when it is combined with Medrogestone.Approved, Investigational
Edetic AcidThe therapeutic efficacy of Edetic Acid can be decreased when used in combination with Medrogestone.Approved, Vet Approved
EdoxabanThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Medrogestone.Approved
EmpagliflozinThe serum concentration of Empagliflozin can be decreased when it is combined with Medrogestone.Approved
EnoxaparinThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Medrogestone.Approved
Ethyl biscoumacetateThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Medrogestone.Withdrawn
ExenatideThe serum concentration of Exenatide can be decreased when it is combined with Medrogestone.Approved, Investigational
FeprazoneThe serum concentration of Medrogestone can be decreased when it is combined with Feprazone.Experimental
Ferulic acidThe therapeutic efficacy of Ferulic acid can be decreased when used in combination with Medrogestone.Experimental
FluindioneThe therapeutic efficacy of Fluindione can be decreased when used in combination with Medrogestone.Approved, Investigational
FondaparinuxThe therapeutic efficacy of Fondaparinux can be decreased when used in combination with Medrogestone.Approved, Investigational
Fondaparinux sodiumThe therapeutic efficacy of Fondaparinux sodium can be decreased when used in combination with Medrogestone.Approved, Investigational
GabexateThe therapeutic efficacy of Gabexate can be decreased when used in combination with Medrogestone.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Medrogestone.Experimental
GlibornurideThe serum concentration of Glibornuride can be decreased when it is combined with Medrogestone.Investigational, Withdrawn
GliclazideThe serum concentration of Gliclazide can be decreased when it is combined with Medrogestone.Approved
GlimepirideThe serum concentration of Glimepiride can be decreased when it is combined with Medrogestone.Approved
GlipizideThe serum concentration of Glipizide can be decreased when it is combined with Medrogestone.Approved, Investigational
GliquidoneThe serum concentration of Gliquidone can be decreased when it is combined with Medrogestone.Approved, Investigational
GlyburideThe serum concentration of Glyburide can be decreased when it is combined with Medrogestone.Approved
GusperimusThe serum concentration of Gusperimus can be decreased when it is combined with Medrogestone.Investigational
HeparinThe therapeutic efficacy of Heparin can be decreased when used in combination with Medrogestone.Approved, Investigational
HexobarbitalThe serum concentration of Medrogestone can be decreased when it is combined with Hexobarbital.Approved
Human C1-esterase inhibitorMedrogestone may increase the thrombogenic activities of Human C1-esterase inhibitor.Approved
IdraparinuxThe therapeutic efficacy of Idraparinux can be decreased when used in combination with Medrogestone.Investigational
Insulin AspartThe serum concentration of Insulin Aspart can be decreased when it is combined with Medrogestone.Approved
Insulin DetemirThe serum concentration of Insulin Detemir can be decreased when it is combined with Medrogestone.Approved
Insulin GlargineThe serum concentration of Insulin Glargine can be decreased when it is combined with Medrogestone.Approved
Insulin GlulisineThe serum concentration of Insulin Glulisine can be decreased when it is combined with Medrogestone.Approved
Insulin HumanThe serum concentration of Insulin Human can be decreased when it is combined with Medrogestone.Approved, Investigational
Insulin LisproThe serum concentration of Insulin Lispro can be decreased when it is combined with Medrogestone.Approved
Insulin PorkThe serum concentration of Insulin Pork can be decreased when it is combined with Medrogestone.Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Medrogestone.Experimental
LepirudinThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Medrogestone.Approved
LetaxabanThe therapeutic efficacy of Letaxaban can be decreased when used in combination with Medrogestone.Investigational
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Medrogestone.Approved
LiraglutideThe serum concentration of Liraglutide can be decreased when it is combined with Medrogestone.Approved
LymecyclineThe serum concentration of Medrogestone can be decreased when it is combined with Lymecycline.Approved, Investigational
MelagatranThe therapeutic efficacy of Melagatran can be decreased when used in combination with Medrogestone.Experimental
MetforminThe serum concentration of Metformin can be decreased when it is combined with Medrogestone.Approved
MethacyclineThe serum concentration of Medrogestone can be decreased when it is combined with Methacycline.Approved, Investigational
MethohexitalThe serum concentration of Medrogestone can be decreased when it is combined with Methohexital.Approved
MethylphenobarbitalThe serum concentration of Medrogestone can be decreased when it is combined with Methylphenobarbital.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Medrogestone.Experimental
MezlocillinThe serum concentration of Medrogestone can be decreased when it is combined with Mezlocillin.Approved, Investigational
MiglitolThe serum concentration of Miglitol can be decreased when it is combined with Medrogestone.Approved
MiglustatThe serum concentration of Miglustat can be decreased when it is combined with Medrogestone.Approved
MinocyclineThe serum concentration of Medrogestone can be decreased when it is combined with Minocycline.Approved, Investigational
MitiglinideThe serum concentration of Mitiglinide can be decreased when it is combined with Medrogestone.Approved, Investigational
NadroparinThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Medrogestone.Approved, Investigational
NafamostatThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Medrogestone.Approved, Investigational
NateglinideThe serum concentration of Nateglinide can be decreased when it is combined with Medrogestone.Approved, Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Medrogestone.Experimental, Investigational
OtamixabanThe therapeutic efficacy of Otamixaban can be decreased when used in combination with Medrogestone.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Medrogestone.Approved
OxyphenbutazoneThe serum concentration of Medrogestone can be decreased when it is combined with Oxyphenbutazone.Approved, Withdrawn
OxytetracyclineThe serum concentration of Medrogestone can be decreased when it is combined with Oxytetracycline.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Medrogestone.Approved, Vet Approved
PenimepicyclineThe serum concentration of Medrogestone can be decreased when it is combined with Penimepicycline.Experimental
Pentaerythritol TetranitrateThe therapeutic efficacy of Pentaerythritol Tetranitrate can be decreased when used in combination with Medrogestone.Approved
PentobarbitalThe serum concentration of Medrogestone can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
Pentosan PolysulfateThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Medrogestone.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Medrogestone.Experimental
PhenforminThe serum concentration of Phenformin can be decreased when it is combined with Medrogestone.Approved, Investigational, Withdrawn
PhenindioneThe therapeutic efficacy of Phenindione can be decreased when used in combination with Medrogestone.Approved, Investigational
PhenobarbitalThe serum concentration of Medrogestone can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenprocoumonThe therapeutic efficacy of Phenprocoumon can be decreased when used in combination with Medrogestone.Approved, Investigational
PhenytoinThe serum concentration of Medrogestone can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PioglitazoneThe serum concentration of Pioglitazone can be decreased when it is combined with Medrogestone.Approved, Investigational
PiperacillinThe serum concentration of Medrogestone can be decreased when it is combined with Piperacillin.Approved
PivampicillinThe serum concentration of Medrogestone can be decreased when it is combined with Pivampicillin.Approved
PramlintideThe serum concentration of Pramlintide can be decreased when it is combined with Medrogestone.Approved, Investigational
PrimidoneThe serum concentration of Medrogestone can be decreased when it is combined with Primidone.Approved, Vet Approved
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Medrogestone.Experimental
Protein CThe therapeutic efficacy of Protein C can be decreased when used in combination with Medrogestone.Approved
Protein S humanThe therapeutic efficacy of Protein S human can be decreased when used in combination with Medrogestone.Approved
ProtocatechualdehydeThe therapeutic efficacy of Protocatechualdehyde can be decreased when used in combination with Medrogestone.Approved
RepaglinideThe serum concentration of Repaglinide can be decreased when it is combined with Medrogestone.Approved, Investigational
ReviparinThe therapeutic efficacy of Reviparin can be decreased when used in combination with Medrogestone.Approved, Investigational
RivaroxabanThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Medrogestone.Approved
RolitetracyclineThe serum concentration of Medrogestone can be decreased when it is combined with Rolitetracycline.Approved
RosiglitazoneThe serum concentration of Rosiglitazone can be decreased when it is combined with Medrogestone.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Medrogestone.Approved
SecobarbitalThe serum concentration of Medrogestone can be decreased when it is combined with Secobarbital.Approved, Vet Approved
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Medrogestone.Approved, Investigational
SotagliflozinThe serum concentration of Sotagliflozin can be decreased when it is combined with Medrogestone.Investigational
SulfinpyrazoneThe serum concentration of Medrogestone can be decreased when it is combined with Sulfinpyrazone.Approved
SulodexideThe serum concentration of Sulodexide can be decreased when it is combined with Medrogestone.Approved, Investigational
TalampicillinThe serum concentration of Medrogestone can be decreased when it is combined with Talampicillin.Experimental
TetracyclineThe serum concentration of Medrogestone can be decreased when it is combined with Tetracycline.Approved, Vet Approved
ThiamylalThe serum concentration of Medrogestone can be decreased when it is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe serum concentration of Medrogestone can be decreased when it is combined with Thiopental.Approved, Vet Approved
TigecyclineThe serum concentration of Medrogestone can be decreased when it is combined with Tigecycline.Approved
TolazamideThe serum concentration of Tolazamide can be decreased when it is combined with Medrogestone.Approved, Investigational
TolbutamideThe serum concentration of Tolbutamide can be decreased when it is combined with Medrogestone.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Medrogestone.Approved, Investigational
TroglitazoneThe serum concentration of Troglitazone can be decreased when it is combined with Medrogestone.Investigational, Withdrawn
TroxerutinThe therapeutic efficacy of Troxerutin can be decreased when used in combination with Medrogestone.Investigational
UlipristalThe therapeutic efficacy of Medrogestone can be decreased when used in combination with Ulipristal.Approved
VildagliptinThe serum concentration of Vildagliptin can be decreased when it is combined with Medrogestone.Approved, Investigational
VogliboseThe serum concentration of Voglibose can be decreased when it is combined with Medrogestone.Approved, Investigational
WarfarinThe therapeutic efficacy of Warfarin can be decreased when used in combination with Medrogestone.Approved
XimelagatranThe therapeutic efficacy of Ximelagatran can be decreased when used in combination with Medrogestone.Approved, Investigational, Withdrawn
Food Interactions
Not Available

References

General References
  1. Revesz C, Chappel CI: Biological activity of medrogestone: a new orally active progestin. J Reprod Fertil. 1966 Dec;12(3):473-87. [PubMed:4288903]
  2. Jones & Bartlett (2016). 2016 Nurse's drug handbook (15th ed., pp. 985). Jones and Bartlett Publishers Inc..
  3. Clark M., Harvey R., Finkel R., Rey J. and Whalen K. (2011). Pharmacology (5th ed.). Lippincott Williams & Wilkins.
  4. Hinman F. (1983). Benign prostatic hypertrophy (1st ed.). Kingsport Press.
  5. Lobo R., Crosignani P., Paoletti R. and Bruschi F. (2002). Women's health and menopause (1st ed.). Kluwer Academic Publishers.
  6. Carp H. (2015). Progestogens in obstetrics and gynecology.. Springer.
  7. Health Canada [Link]
External Links
PubChem Compound
9949848
PubChem Substance
310265040
ChemSpider
8125459
ChEBI
135446
ChEMBL
CHEMBL2106825
ATC Codes
G03FB07 — Medrogestone and estrogenG03DB03 — Medrogestone
MSDS
Download (78.8 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral5 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)144-146ºC'MSDS'
boiling point (°C)467.17ºC at 760 mmHg'MSDS'
water solubility5.34e-06 mol/L'MSDS'
logP4.45'MSDS'
Predicted Properties
PropertyValueSource
Water Solubility0.00404 mg/mLALOGPS
logP4.35ALOGPS
logP4.59ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)19.18ChemAxon
pKa (Strongest Basic)-4.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area34.14 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity102.6 m3·mol-1ChemAxon
Polarizability40.37 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Pregnane steroids
Direct Parent
Gluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
20-oxosteroids / 3-oxosteroids / Cyclohexenones / Organic oxides / Hydrocarbon derivatives
Substituents
Progestogin-skeleton / 20-oxosteroid / Oxosteroid / 3-oxosteroid / Cyclohexenone / Cyclic ketone / Ketone / Organic oxygen compound / Organic oxide / Hydrocarbon derivative
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Ligand
General Function
Zinc ion binding
Specific Function
The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Progesterone receptor ...
Gene Name
PGR
Uniprot ID
P06401
Uniprot Name
Progesterone receptor
Molecular Weight
98979.96 Da
References
  1. Clark M., Harvey R., Finkel R., Rey J. and Whalen K. (2011). Pharmacology (5th ed.). Lippincott Williams & Wilkins.

Carriers

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Binder
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Lobo R., Crosignani P., Paoletti R. and Bruschi F. (2002). Women's health and menopause (1st ed.). Kluwer Academic Publishers.
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Binder
General Function
Androgen binding
Specific Function
Functions as an androgen transport protein, but may also be involved in receptor mediated processes. Each dimer binds one molecule of steroid. Specific for 5-alpha-dihydrotestosterone, testosterone...
Gene Name
SHBG
Uniprot ID
P04278
Uniprot Name
Sex hormone-binding globulin
Molecular Weight
43778.755 Da
References
  1. Carp H. (2015). Progestogens in obstetrics and gynecology.. Springer.
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Binder
General Function
Steroid binding
Specific Function
Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
Gene Name
SERPINA6
Uniprot ID
P08185
Uniprot Name
Corticosteroid-binding globulin
Molecular Weight
45140.49 Da
References
  1. Carp H. (2015). Progestogens in obstetrics and gynecology.. Springer.

Drug created on September 23, 2015 10:20 / Updated on January 10, 2018 03:46